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Introduction: Improving health-related quality of life (HRQoL) in COPD patients is an important phar-
macotherapeutic objective. This study investigated the extent, consistency, and durability of tiotropium
maintenance therapy impact on HRQoL in moderate-to-very severe COPD.
Methods: Patients received once-daily tiotropium 18 mg (n ¼ 5244) or placebo (n ¼ 4799) via Handi-
Haler® (10 trials), or once-daily tiotropium 5 mg (n ¼ 2622) or placebo (n ¼ 2618) via Respimat® inhaler
(3 trials). St George's Respiratory Questionnaire (SGRQ) total scores were measured at baseline, and 6
months (13 trials) and 1 year (9 trials) from treatment start. Adjusted mean differences between
treatments for change from baseline in total scores were calculated at each time-point for each trial.
Responder and deteriorator rates (decrease or increase in score 4 units from baseline, respectively), net
beneﬁt (responder rate increase plus deteriorator rate decrease), and cumulative improvement and
deterioration were determined.
Results: Adjusted mean total score differences between treatments for change from baseline were sig-
niﬁcant (p < 0.05) in favor of tiotropium in 10/13 trials at 6 months and in 8/9 trials at 1 year. In all trials,
estimated differences in responder rates between treatments favored tiotropium (signiﬁcant [p < 0.05]:
5/13 trials at 6 months; 8/9 trials at 1 year). Net beneﬁt favored tiotropium and cumulative improvement
rates were consistently greater and deterioration rates consistently lower for tiotropium versus placebo.
Conclusions: Tiotropium maintenance therapy signiﬁcantly and consistently improved HRQoL in
moderate-to-very severe COPD patients in a durable manner. These results may provide a benchmark for
assessing beneﬁts on HRQoL of other COPD treatments.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ry disease; EXACTT, Exercise Endurance and COPD Patients Treated with Tiotropium; FEV1, forced expiratory volume in
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Chronic obstructive pulmonary disease (COPD) is characterized
by a progressive decline in lung function, resulting in deleterious
effects on patients' exercise tolerance, functional capacity, and
overall well-being [1]. With an increase in symptoms patients
become less able to work and feel socially isolated, anxious, and
depressed [2e4]. These factors, together with COPD exacerbations,
have a negative effect on patients' health-related quality of life
(HRQoL) [5e7].
Health status instruments, such as the St George's Respiratory
Questionnaire (SGRQ), are intended to assess disease impact on
patients' perception of their ability to lead a useful and fulﬁlling life
and changes in health status resulting from treatment. In COPD,
SGRQ questionnaires have been used in stable disease and during
exacerbations [6].
The SGRQ is a self-administered, respiratory disease-speciﬁc,
health-status questionnaire developed by Jones et al. [8,9], which
allows direct comparisons between patient populations and treat-
ment groups to quantify beneﬁts of an intervention. A responder/
deteriorator analysis calculates the proportion of patients who
decrease (i.e., improve) or increase (i.e., deteriorate) SGRQ total
scores by more than the minimal clinically important difference
(MCID) of 4 units [10e12]. In treatment comparisons, net response
rate, or net beneﬁt, is calculated as the difference in the sum of
beneﬁts from the increase in responder rate and decrease in
deteriorator rate between treatments.
The long-acting muscarinic antagonist (LAMA), tiotropium,
administered by HandiHaler® or Respimat® inhalers, has been
conﬁrmed in many clinical trials, performed over 13 years, to
improve SGRQ total score, and an overall estimate of its efﬁcacywas
reported in a formal meta-analysis of SGRQ total scores in COPD
[13]. The magnitude of SGRQ responses achieved with some newly
licensed LAMAs has varied, and in most reports improvement
(group mean difference from placebo) has not exceeded the MCID
[14e21]. We have analyzed the consistency of changes in SGRQ
total score observed in patients with COPD receiving tiotropium in
13 previously reported clinical trials [22e31]. We have also
expressed our ﬁndings as responder and deteriorator rates, net
beneﬁt, and cumulative improvement and deterioration rates,
which were not reported in the original papers; these analyses may
be more clinically useful when evaluating beneﬁts achieved with
maintenance treatment in patients with COPD and when
comparing different interventions.
2. Methods
2.1. Study trials
All Boehringer Ingelheim-sponsored clinical trials of tiotropium
monotherapy in COPD that met the criteria of6months' duration,
placebo controlled, double blind, and in which SGRQ data were
collected were included in the analyses. Patients were randomized
to receive once-daily tiotropium 18 mg or placebo delivered via
HandiHaler® (Boehringer Ingelheim, Ingelheim am Rhein, Ger-
many) in 10 trials and once-daily tiotropium 5 mg or placebo
delivered via Respimat® inhaler (Boehringer Ingelheim, Ingelheim
am Rhein, Germany) in three trials. Based on past research, tio-
tropium doses delivered via HandiHaler and Respimat devices were
considered comparable in terms of pharmacokinetics, efﬁcacy, and
safety [32e34]. In some trials, patients were also randomized to
receive tiotropium 10 mg delivered via Respimat® inhaler or an
alternative active comparator; data from these treatment arms
were not included in the analyses.
With the exception of two trials (one of 2 years' duration andone of 4 years' duration), the trials were 1 year or less in duration
from start of treatment. Our analyses, focused on two time-points:
6 months and 1 year.
The primary papers for each trial have been published [22e31]
and their designs are summarized in Supplementary Table A1.
2.2. Study participants
Patients in all trials were of either sex, aged 40 years, with a
smoking history of 10 pack-years and moderate-to-very severe
COPD. Lung function inclusion criteria for patients (forced expira-
tory volume in 1 s [FEV1] % predicted normal [35,36] and FEV1/
forced vital capacity [FVC]) in each trial are provided in
Supplementary Table A1.
All patients could remain on their usual COPDmedications, with
the exception that inhaled anticholinergics, other than study drug,
were not permitted in any trial. In addition, in all trials except four
(205.235 [UPLIFT], 205.259 [SAFE], 205.368 [EXACTT], and 205.372)
long-acting b-agonists (LABAs) were not allowed.
Details of the inclusion and exclusion criteria are provided in the
published primary papers for each trial, as cited in Table 1 [22e31].
2.3. St George's Respiratory Questionnaire
The SGRQ focusses on three major HRQoL domains: symptoms;
activity; and impacts [8,9]. Scores from the domains are combined
into a total score, which is on a scale of 0e100, with higher scores
associated with poorer HRQoL. In this study, we have analyzed data
for SGRQ total scores, rather than for the separate domains.
For all 13 trials, SGRQ total scores, for patients within each
treatment group, were measured at baseline and 6 months from
start of treatment. In addition, in nine trials, SGRQ total scores were
also measured at 1 year from start of treatment. In all trials, SGRQ
data were either a primary or secondary outcome measure
(Supplementary Table A1).
Within-treatment changes in SGRQ total score from baseline at
6 months and 1 year from start of treatment were calculated on a
trial-by-trial basis. Adjusted mean differences between treatments
(tiotropium versus placebo) for change from baseline at each time-
point for each trial were calculated. The MCID for SGRQ total score
is a difference of 4 units [10e12]. Responder and deteriorator rates
at 6 months and 1 year from start of treatment were calculated. A
responder was deﬁned as a patient who achieved a reduction of at
least 4 units in SGRQ total score from baseline and a deteriorator
was deﬁned as a patient who had an increase of at least 4 units in
SGRQ total score from baseline.
Net beneﬁt was calculated as the sum of beneﬁts from the in-
crease in responder and decrease in deteriorator rates between
treatments, assuming equal weight should be given to both. For the
net beneﬁt analysis, two cut-off points were evaluated, based on a
change from baseline in SGRQ total score of 4 and  8 units.
For each trial, cumulative improvement and cumulative dete-
rioration were determined. Patients were considered to have
improved if their change from baseline in SGRQ total score was
negative or to have deteriorated if their SGRQ total score increased
from baseline. The cut-off ranges examined were between 12 and
0 units for cumulative improvement and between 0 and 12 units for
cumulative deterioration. For the two largest trials, 205.235 (UP-
LIFT) and 205.372 (representing 64% of the overall study population
with baseline scores), the range was extended to20 to 20 units at
1 year from start of treatment. To explain the cumulative nature of
the analysis, as the cut-off increases the number of patients at each
cut-off decreases (e.g., the set of patients whose score decreased by
1 point from baseline includes patients whose score decreased by 2
points from baseline).
Table 1
Baseline demographic and clinical characteristics (treated set).
BI trial number
(trial name)
ClinicalTrials.gov
number
primary
reference
Treatment N Males,
n (%)
Age, years,
mean ± SD (range)
Smoking History, pack-
years, mean ± SD
Duration of COPD,
years, mean ± SD
Pre-BD FEV1
% predicted,
mean ± SD
Pre-BD FEV1/FVC
(%), mean ± SD
SGRQ Total score,
mean ± SD
HandiHaler trials
205.114/117
Casaburi et al.,
2002 [22]
Tiotropium 279 186
(67)
65.0 ± 8.6
(40e85)
64.5 ± 33.1 9.3 ± 8.0 39.2 ± 13.8a 46.2 ± 11.8 47.53 ± 15.90
(n ¼ 265)
Placebo 191 121
(63)
65.5 ± 9.0
(39e81)
60.5 ± 30.2 8.6 ± 6.9 37.7 ± 14.1a 46.2 ± 11.5 49.65 ± 16.31
(n ¼ 171)
205.115/128
Casaburi et al.,
2002 [22]
Tiotropium 271 180
(66)
65.2 ± 8.5
(41e87)
60.6 ± 27.6 8.0 ± 6.6 39.1 ± 13.6a 45.5 ± 11.5 45.68 ± 16.00
(n ¼ 251)
Placebo 180 112
(62)
65.2 ± 8.8
(41e82)
57.4 ± 30.5 7.7 ± 6.7 38.6 ± 14.0a 44.7 ± 11.8 43.90 ± 14.87
(n ¼ 153)
205.130
NCT02172287
Brusasco et al.,
2003 [23]
Tiotropium 209 154
(74)
64.5 ± 7.9
(45e84)
46.9 ± 24.7 9.2 ± 7.8 39.2 ± 11.8b 43.6 ± 9.8 45.19 ± 16.42
(n ¼ 186)
Placebo 201 151
(75)
65.6 ± 7.8
(41e83)
45.5 ± 24.3 9.7 ± 7.9 38.1 ± 11.5b 41.3 ± 8.7 46.45 ± 16.41
(n ¼ 159)
205.137
NCT02173691
Brusasco et al.,
2003 [23]
Tiotropium 193 157
(81)
63.0 ± 8.1
(41e80)
41.1 ± 20.5 8.9 ± 6.7 39.2 ± 11.5b 43.7 ± 9.5 44.54 ± 17.33
(n ¼ 170)
Placebo 199 154
(77)
63.7 ± 9.2
(39e87)
39.2 ± 20.6 9.9 ± 7.0 39.4 ± 12.8b 43.2 ± 9.5 43.29 ± 17.48
(n ¼ 167)
205.230
NCT00274521
Casaburi et al.,
2005 [24]
Tiotropium 55 30 (55) 65.9 ± 8.8
(42e83)
58.6 ± 34.6 9.7 ± 7.6 32.6 ± 12.4a 41.5 ± 10.4 50.41 ± 15.38
(n ¼ 49)
Placebo 53 31 (58) 67.3 ± 6.9
(52e78)
58.8 ± 31.4 8.9 ± 6.6 36.2 ± 12.2a 44.6 ± 11.2 46.58 ± 16.12
(n ¼ 47)
205.235 (UPLIFT)
NCT00144339
Tashkin et al.,
2008 [25]
Tiotropium 2986 2251
(75)
64.5 ± 8.4
(40e88)
49.0 ± 28.0 9.9 ± 7.6 39.5 ± 12.0b
(n ¼ 2908)
42.4 ± 10.5
(n ¼ 2908)
44.98 ± 16.97
(n ¼ 2478)
Placebo 3006 2222
(74)
64.5 ± 8.5
(40e88)
48.4 ± 27.9 9.7 ± 7.4 39.3 ± 11.9b
(n ¼ 2937)
42.1 ± 10.5
(n ¼ 2937)
45.07 ± 17.17
(n ¼ 2337)
205.247
NCT00157235
Ambrosino et al.,
2008 [26]
Tiotropium 117 97 (83) 67.8 ± 7.8
(47e83)
38.3 ± 25.2 10.9 ± 9.8
(n ¼ 116)
42.5 ± 13.3b 47.3 ± 11.8 38.30 ± 18.39
(n ¼ 103)
Placebo 117 99 (85) 66.9 ± 7.3
(50e85)
35.0 ± 22.4 11.3 ± 9.5 40.3 ± 12.6b
(n ¼ 116)
45.2 ± 10.4
(n ¼ 116)
39.90 ± 19.52
(n ¼ 104)
205.256 TIPHON)
NCT00274053
Tonnel et al.,
2008 [27]
Tiotropium 266 231
(87)
64.9 ± 9.7
(40e86)
44.4 ± 21.3
(n ¼ 264)
7.9 ± 7.6 47.5 ± 13.3b
(n ¼ 264)
55.3 ± 11.3 45.92 ± 17.68
(n ¼ 247)
Placebo 288 246
(85)
63.5 ± 10.1
(38e85)
43.0 ± 22.5
(n ¼ 285)
8.0 ± 7.9
(n ¼ 286)
46.2 ± 12.4b 54.6 ± 11.3 48.67 ± 17.89
(n ¼ 245)
205.259 (SAFE)
NCT00277264
Chan et al., 2007
[28]
Tiotropium 608 361
(59)
66.8 ± 8.7
(43e92)
50.2 ± 22.6
(n ¼ 607)
9.9 ± 8.1 39.4 ± 13.4a
(n ¼ 607)
46.4 ± 11.6
(n ¼ 607)
45.85 ± 16.98
(n ¼ 501)
305 185
(61)
66.9 ± 9.1
(40e90)
51.0 ± 26.3 9.9 ± 7.9 39.3 ± 13.6a
(n ¼ 303)
46.3 ± 11.8
(n ¼ 303)
47.64 ± 17.00
(n ¼ 233)
205.368
(EXACTT)
NCT00525512
Cooper et al.,
2013 [29]
Tiotropium 260 199
(77)
64.7 ± 8.2 N/A 52.2 ± 29.0 8.7 ± 6.3 38.3 ± 10.9b
(n ¼ 259)
45.2 ± 11.0
(n ¼ 259)
42.99 ± 16.98
(n ¼ 220)
Placebo 259 202
(78)
64.5 ± 8.5
N/A
51.0 ± 26.3 8.8 ± 7.0 38.3 ± 11.5b
(n ¼ 258)
45.6 ± 10.8
(n ¼ 258)
41.76 ± 17.49
(n ¼ 216)
Respimat trials
205.254
NCT00168844
Bateman et al.,
2010 [30]
Tiotropium 332 243
(73)
65.0 ± 8.2
(42e90)
46.8 ± 28.6 8.6 ± 6.5 38.3 ± 11.0b 42.9 ± 10.8 45.44 ± 16.60
(n ¼ 318)
Placebo 319 252
(79)
64.7 ± 8.9
(40e87)
45.8 ± 25.4 9.9 ± 8.1 37.8 ± 11.5b 43.1 ± 10.8 45.28 ± 17.91
(n ¼ 275)
205.255
NCT00168831
Bateman et al.,
2010 [30]
Tiotropium 338 248
(73)
64.4 ± 8.9
(38e85)
47.4 ± 25.1 8.1 ± 6.4 39.2 ± 12.0b
(n ¼ 335)
43.0 ± 11.3
(n ¼ 335)
44.17 ± 16.71
(n ¼ 310)
Placebo 334 235
(70)
65.7 ± 8.4
(41e87)
49.326.7 9.0 ± 6.8 38.8 ± 11.7b 42.4 ± 11.1 45.98 ± 16.13
(n ¼ 276)
205.372
NCT00387088
Bateman et al.,
2010 [31]
Tiotropium 1952 1524
(78)
64.8 ± 9.1
N/A
46.0 ± 26.1 8.3 ± 7.0 39.9 ± 12.0b 47.2 ± 10.8 42.94 ± 17.99
(n ¼ 1691)
Placebo 1965 1513
(77)
64.8 ± 9.0
N/A
45.0 ± 26.5 8.1 ± 6.5 39.8 ± 12.0b 46.7 ± 10.7 44.12 ± 18.28
(n ¼ 1670)
BD, bronchodilator; EXACTT, Exercise Endurance and COPD Patients Treated with Tiotropium; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; N/A, not
available; qd, once daily; SAFE, Spiriva Assessment of FEV1; SD, standard deviation; TIPHON, Tiotropium: Inﬂuence sur la Perception de lamelioration des activites Habituelles
Objectivee par une echelle Numerique; UPLIFT, Understanding Potential Long-term Impacts on Function with Tiotropium.
Number of patients is given in column 3 unless speciﬁed elsewhere.
a % Predicted according to Morris [35].
b % Predicted according to European Community for Coal and Steel [36].
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The full analysis set (FAS) included all patients with a baseline
SGRQ total score and at least one non-missing score post-
randomization. The exception to this was for 205.235 (UPLIFT),where the FAS included all patients with a baseline SGRQ total
score and at least two non-missing scores after 6 months of
treatment. The UPLIFT trial investigated the slope of change in
SGRQ as a secondary endpoint, so required two non-missing SGRQ
scores. All analyses were performed with SAS software, version 9.2
D.P. Tashkin et al. / Respiratory Medicine 120 (2016) 91e10094(SAS Institute, Cary, NC, USA).
For SGRQ total score, adjusted mean differences in treatments
(tiotropium versus placebo) for change from baseline were calcu-
lated at each time-point using mixed model repeated measures
(MMRM). All visits were used in the MMRMmodels for estimation.
Means were adjusted for treatment, visit, baseline SGRQ total score,
and interactions treatment  visit and baseline  visit. For calcu-
lation of responder rates, deteriorator rates, net beneﬁt, cumulative
improvement, and cumulative deterioration, multiple imputation
was used to impute missing SGRQ total scores using a regression
model based on previously non-missing SGRQ total scores. Imputed
data were used for inference. Differences in responder rates,
deteriorator rates, and net beneﬁt were compared between treat-
ments using the z-test. There was no control of type I error for the
analyses; therefore a p-value <0.05 was considered statistically
signiﬁcant in a nominal manner.
A meta-analysis was performed for SGRQ total score (inverse
variance, ﬁxed-effect model); I2 was used to assess heterogeneity
among study results.
3. Results
3.1. Demographic and clinical characteristics
The demographic and clinical characteristics of patients were
generally similar across the clinical trials and treatment groups
(Table 1). In the HandiHaler trials, 5244 patients received tio-
tropium and 4799 received placebo, and in the Respimat trials,
2622 patients received tiotropium and 2618 received placebo. The
majority of patients were male.
3.2. SGRQ total scores
In total, 12,842 patients had baseline SGRQ total scores;
mean ± SD for each trial are provided in Table 1. Estimated mean
changes from baseline in total scores at 6 months and 1 year from
start of treatment are provided in Supplementary Table A2. Esti-
mated mean differences between treatments in change from
baseline in total scores were statistically signiﬁcant (p < 0.05) in
favor of tiotropium in 10 of the 13 trials at 6 months and in eight of
the nine trials at 1 year (Fig. 1). The MCID of a 4-point decrease
(tiotropium versus placebo difference in change from baseline) was
exceeded in two HandiHaler trials at 6 months and in one Handi-
Haler trial at 1 year; theMCID between tiotropium and placebowas
not met in the Respimat trials at either time-point.
Estimated mean difference in total score between tiotropium
and placebo for change from baseline in the two trials that
continued beyond 1 year from start of treatment, the 4-year UPLIFT
(205.235) and 2-year EXACTT (205.368) trials, are shown in
Supplementary Table A3.
A meta-analysis for mean difference in SGRQ total score (as
change from baseline) between tiotropium and placebo at 1 year
from start of treatment resulted in a mean of 3.0 SGRQ total score
units (95% CI e3.4 to 2.5) with no observed heterogeneity be-
tween trials (c2 ¼ 3.29, p ¼ 0.91, I2 ¼ 0%; test for overall effect:
z ¼ 12.25, p < 0.0001; Supplementary Fig. A1).
3.3. Responder and deteriorator rates
Estimated SGRQ responder rates at 6 months and 1 year from
start of treatment are shown in Supplementary Table A4. At both
time-points, all estimated differences in responder rates for tio-
tropium versus placebo were positive in favor of tiotropium (Fig. 2).
At 6 months, statistical signiﬁcance (p < 0.05) in favor of tiotropium
for estimated differences in responder rates between treatmentswas achieved in three out of the 10 HandiHaler trials and two out of
three Respimat trials and, at 1 year, it was achieved in ﬁve of the six
HandiHaler trials and in all three Respimat trials.
Estimated SGRQ deteriorator rates at 6 months and 1 year from
start of treatment are given in Supplementary Table A5. In each
trial, at both time-points, the estimated difference in deteriorator
rates for tiotropium versus placebo was negative in favor of tio-
tropium (Fig. 3). At 6 months, statistical signiﬁcance (p < 0.05) in
favor of tiotropium for deteriorator rates was achieved in six out of
the 10 HandiHaler trials and two of the three Respimat trials and, at
1 year, it was achieved in three of the six HandiHaler trials and in all
three Respimat trials.
Fig. 4 shows the proportions of patients who responded, dete-
riorated, and neither responded nor deteriorated as measured by a
change in SGRQ total score from baseline of 4 units at 1 year from
start of treatment (equivalent data for a 8-unit change from
baseline to 1 year are provided in Supplementary Fig. A2). In each
trial, there was a higher responder rate and a lower deteriorator
rate with tiotropium compared with placebo. At 1 year, at the 4
and  8 cut-points, there were more responders than deteriorators
in the tiotropium groups in all nine trials; whereas, in the placebo
groups at these cut-points three out of the nine trials had more
deteriorators than responders. The proportion of patients who
neither responded nor deteriorated, as measured by a positive or
negative change in SGRQ total score from baseline of <4 units at 1
year, accounted for 25e29% in the tiotropium groups and 25e32%
in the placebo groups.
SGRQ responder rates for trials continuing beyond 1 year from
start of treatment, the 4-year UPLIFT (205.235) and 2-year EXACTT
(205.368), are given in Supplementary Table A6.
3.4. Net beneﬁt
In all trials, at 6 months and 1 year from start of treatment,
estimated net beneﬁt for tiotropium versus placebo was positive in
favor of tiotropium (Fig. 5). At 6 months, statistical signiﬁcance
(p < 0.05) in favor of tiotropium was achieved in six out of the 10
HandiHaler trials and two of the three Respimat trials, and, at 1
year, it was achieved in four of the six HandiHaler trials and in all
three Respimat trials. At 1 year compared with 6 months, three
HandiHaler trials and one Respimat trial showed a net beneﬁt in-
crease and two HandiHaler trials showed a net beneﬁt decrease; in
the remaining one HandiHaler and two Respimat trials, net beneﬁts
were similar at 6 months and 1 year (Fig. 5).
3.5. Cumulative response analyses
Cumulative improvement and cumulative deterioration curves
for SGRQ total score changes from baseline in the range 12
and þ 12 units showed consistent trends across trials at 6 months
and 1 year from start of treatment (Supplementary Fig. A3 and
Fig. 6, respectively). At both time-points, cumulative improvement
rates were consistently greater and deterioration rates consistently
lower for tiotropium versus placebo. Cumulative improvement and
deterioration curves were mostly in parallel between tiotropium
and placebo, suggesting a constant treatment effect that is insen-
sitive to the threshold deﬁning a response. Cumulative curves
tended to ﬂatten towards the extremes; this wasmoremarkedwith
the cumulative deterioration curves, where the placebo and tio-
tropium arms tended to converge. This is evident because few
patients could achieve very large improvement or deterioration.
When cumulative deterioration exceeded 8 units, the relative
beneﬁt of tiotropium versus placebo was eroded in about half the
trials. This phenomenon was generally not seen with large im-
provements. This is seen most clearly in the two largest trials,
Fig. 1. Estimated mean difference between tiotropium and placebo in SGRQ total score change from baseline at 6 months and 1 year from start of treatment: full analysis set.
EXACTT, Exercise Endurance and COPD Patients Treated with Tiotropium; SAFE, Spiriva Assessment of FEV1; SE, standard error of the mean; TIPHON, Tiotropium: Inﬂuence sur la
Perception de lamelioration des activites Habituelles Objectivee par une echelle Numerique; UPLIFT, Understanding Potential Long-term Impacts on Function with Tiotropium.
Fig. 2. Estimated difference in SGRQ responder rates (in % participants) between tiotropium and placebo at 6 months and 1 year in each trial: full analysis set.
A responder was deﬁned as a patient who achieved a reduction of at least 4 units in SGRQ total score from baseline. EXACTT, Exercise Endurance and COPD Patients Treated with
Tiotropium; SAFE, Spiriva Assessment of FEV1; SE, standard error of the mean; TIPHON, Tiotropium: Inﬂuence sur la Perception de lamelioration des activites Habituelles Objectivee
par une echelle Numerique; UPLIFT, Understanding Potential Long-term Impacts on Function with Tiotropium.
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the SGRQ total score changes from baseline range has been
extended to 20 and þ 20 units. The cumulative improvement andcumulative deterioration curves for these two trials were very
similar. In 205.235 (UPLIFT), at 1 year from start of treatment,15% of
patients (12% responders and 3% deteriorators) in the tiotropium
Fig. 3. Estimated difference in SGRQ deteriorator rates (in % participants) between tiotropium and placebo at 6 months and 1 year in each trial: full analysis set. A deteriorator was
deﬁned as a patient who had an increase of at least 4 units in SGRQ total score from baseline. EXACTT, Exercise Endurance and COPD Patients Treated with Tiotropium; SAFE, Spiriva
Assessment of FEV1; SE, standard error of the mean; TIPHON, Tiotropium: Inﬂuence sur la Perception de lamelioration des activites Habituelles Objectivee par une echelle
Numerique; UPLIFT, Understanding Potential Long-term Impacts on Function with Tiotropium.
Fig. 4. Proportions of patients who responded, deteriorated, and neither responded nor deteriorated as measured by change in SGRQ total score from baseline at 1 year from start of
treatment. A responder was deﬁned as a patient who achieved a reduction of at least 4 units in SGRQ total score from baseline and a deteriorator was deﬁned as a patient who had
an increase of at least 4 units in SGRQ total score from baseline. EXACTT, Exercise Endurance and COPD Patients Treated with Tiotropium; Pbo, placebo; SAFE, Spiriva Assessment of
FEV1; Tio, tiotropium; TIPHON, Tiotropium: Inﬂuence sur la Perception de lamelioration des activites Habituelles Objectivee par une echelle Numerique; UPLIFT, Understanding
Potential Long-term Impacts on Function with Tiotropium.
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tremes of, or outside, the range 20 to 20 units and for 205.372
these proportions were 18% of patients (13% responders and 5%
deteriorators).4. Discussion
The aim of these analyses was to assess the effect of tiotropium
delivered as maintenance treatment via either HandiHaler or
Respimat inhalers on HRQoL, expressed in the conventional
Fig. 5. Estimated SGRQ net beneﬁt between tiotropium and placebo at 6 months and 1 year in each trial: full analysis set. Net beneﬁt was calculated as the difference in responder
rate minus the difference in deteriorator rate between the tiotropium and placebo groups. Where a responder was deﬁned as a patient who achieved a reduction of at least 4 units
in SGRQ total score from baseline and a deteriorator was deﬁned as a patient who had an increase of at least 4 units in SGRQ total score from baseline. EXACTT, Exercise Endurance
and COPD Patients Treated with Tiotropium; SAFE, Spiriva Assessment of FEV1; SE, standard error of the mean; TIPHON, Tiotropium: Inﬂuence sur la Perception de lamelioration des
activites Habituelles Objectivee par une echelle Numerique; UPLIFT, Understanding Potential Long-term Impacts on Function with Tiotropium.
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(responder and deteriorator rates, net beneﬁt, and cumulative
improvement and deterioration rates) in patients with moderate-
to-very severe COPD. An additional aim was to assess the consis-
tency of the impact of tiotropium on the SGRQ response when
measured using these different methods. Data were derived from
13 clinical trials, which covered a wide geographical range, span-
ning ﬁve continents, and were performed over a period of 13 years
(Supplementary Table A1). The results conﬁrm the general consis-
tency in impact of tiotropium versus placebo on HRQoL, as
measured by SGRQ total score, between trials, although not uni-
form in all trials. Possible explanations for variations in results
between trials include differing trial designs, patient characteris-
tics, and use of concomitant therapies, and, in some trials, relatively
high placebo responses, as discussed below.
Comparable improvements in HRQoL, measured by SGRQ total
score, were seen in patients with COPD receiving tiotropium
maintenance therapy, whether delivered via HandiHaler or Respi-
mat. In all trials, at 6 months and 1 year from the start of treatment,
responder rates were greater and deteriorator rates were lower
with tiotropium compared with placebo. As a consequence, net
beneﬁt in all trials was also greater with tiotropium compared with
placebo. Cumulative improvement was greater and cumulative
deterioration lower for tiotropium compared with placebo, with
consistent and durable trends across trials at 6 months and 1 year.
There was a tendency for the cumulative deterioration curves for
tiotropium and placebo to converge at the higher unit scores for
change in SGRQ total score from baseline. This may be due to a ﬂoor
effect, in that patients receiving either tiotropium or placebo had
little room for worsening bymore than 12 SGRQ units. Convergence
of the curves might also be speculated to be the result of factors
other than COPD, including comorbidities, contributing to the
extreme improvement or deterioration observed.The magnitude of treatment effects differed slightly between
trials, possibly due to variations in study design and participant
characteristics. A meta-analysis of adjusted mean difference in
SGRQ total score (as change from baseline) between tiotropium and
placebo at 1 year from start of treatment showed a 2.97 unit
change, indicating HRQoL improvement in patients treated with
tiotropium; however, this value was less than the MCID of 4 units.
Heterogeneity between trials was not observed in the meta-
analysis, but the two largest trials, 205.235 (UPLIFT) and 205.372,
dominated, with weightings of 47% and 24%, respectively. Our re-
sults are similar to the meta-analysis mean value of2.89, reported
by Karner et al. [13], which included several trials in common with
those in our study; our heterogeneity test results were also similar
to those of Karner et al. [13]. For a study population to exceed the
MCID it would require 50% of patients (assuming a normal distri-
bution) to exceed the MCID, which is a very large effect. This
analysis has shown that the net beneﬁt rate across the 13 trials was
z20%.
Differences in permitted background therapies may have
contributed to variations in treatment effects. In all trials, inhaled
corticosteroid (ICS) use was permitted at baseline and throughout
the treatment period, if at a pre-trial stabilized dose rate. In addi-
tion, in four trials, 205.235 (UPLIFT), 205.259 (SAFE), 205.368
(EXACTT), and 205.372, concomitant use of LABAs and/or ICS was
permitted, at baseline and during the treatment period. Although
ICS only was allowed in all trials, the four permitting LABA/ICS use
dominated the overall investigation population, comprising ~80% of
all patients at 1 year from start of treatment; this dominance may
account for the meta-analysis MCID of 4 units not being reached.
The magnitude of SGRQ responses achieved with some newly
licensed LAMAs in clinical trials may also have been affected by
allowed or non-allowed concomitant background therapies
[14e21].
Fig. 6. Cumulative improvement and deterioration curves for tiotropium and placebo at 1 year: full analysis set. Patients were considered to have improved if they had a decrease in
SGRQ total score from baseline and to have deteriorated if they had an increase in score from baseline. Change from baseline was examined over the range 12 to 12 units. EXACTT,
Exercise Endurance and COPD Patients Treated with Tiotropium; Pbo, placebo; SAFE, Spiriva Assessment of FEV1; Tio, tiotropium; TIPHON, Tiotropium: Inﬂuence sur la Perception
de lamelioration des activites Habituelles Objectivee par une echelle Numerique; UPLIFT, Understanding Potential Long-term Impacts on Function with Tiotropium.
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there was an improvement in SGRQ total score in the placebo group
compared with baseline (i.e., any score decrease from baseline); at
1 year, six of the nine trials had an improved placebo SGRQ score.
This improvement phenomenon, known as the ‘Hawthorne effect’,
has been noted previously in relation to SGRQ scores in clinical
trials with COPD [37,38], and it is thought to arise because patients
participating in trials may receive a better standard of care than
usual care, and have greater compliance with concomitant thera-
pies. The extent of improvement as a result of the Hawthorne effect
is generally thought to be a decrease (improvement) in SGRQ score
of around 2e3 units [12]. In the placebo groups, a decrease in score
of >3 units, was seen at 6 months from the start of treatment in
three trials, and at 1 year in one trial. The improvements in SGRQ
score seen in the placebo group may also have contributed to the
MCID of a 4-point decrease (tiotropiumversus placebo difference in
change from baseline) not being met in some of the trials.
Two of the trials included in our analyses, EXACTT (205.368)
[29] and UPLIFT (205.235) [25], had treatment periods lasting >1
year, the maximum time covered by our analyses. These trials
support our ﬁnding of a long-term sustained beneﬁt of mainte-
nance treatment with tiotropium. After 2 years of treatment in theEXACTT trial, SGRQ total scores had improved from baseline in
patients treated with tiotropium and worsened in those treated
with placebo. Throughout the 4-year UPLIFT trial, a sustained and
signiﬁcant beneﬁt of tiotropium was also observed compared with
placebo. After an initial period of improvement, there was an up-
ward trajectory of SGRQ total scores (i.e., deterioration) in both
treatment groups beginning 6 months to a year after randomiza-
tion, which was consistent with age-related worsening of HRQoL.
The rate of increase in SGRQ score in the tiotropium group paral-
leled that in the placebo group, indicating the beneﬁcial effect of
tiotropium compared with placebo persisted over time. The pro-
portions of patients with a 4-unit improvement (i.e., score
decrease) from baseline were signiﬁcantly higher (p < 0.001) for
tiotropium compared with placebo at 6 months through 4 years.
However, it was reported that annual rates of increase in SGRQ total
score (i.e., HRQoL worsening) over the 4 years were not signiﬁ-
cantly different between the two treatments. In the EXACTT trial,
the proportions of patients with a 4-unit improvement from
baseline were also higher for tiotropium compared with placebo at
6 months through 2 years, but differences were not statistically
signiﬁcant, possibly due to the small sample size or potential
impact of formal exercise endurance testing during the trial on
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endurance exercise trial. In both trials, decline in responder rates
versus baseline over time in both treatment groups probably re-
ﬂects the progressive character of the disease.
Examination of the relative responder and deteriorator results
at 1 year reveals a general pattern of more responders than dete-
riorators in the tiotropium groups for all nine trials (Fig. 4). In
contrast, in three of the nine trials, more deteriorators than re-
sponders were noted in the placebo groups. These three trials are of
note as two of them (205.114/117 and 115/128) are trials conducted
as part of the basic registration package with limited background
therapy, and it is possible to hypothesize that in the placebo arms
this provided an enhanced opportunity to detect a loss of HRQoL
over the 1-year trial duration. In the third trial, EXACTT (205.368),
exercise testing may have increased the potential for patients to
detect changes in HRQoL. These observations support the view that
study design should be carefully considered when assessing
HRQoL.
Strengths of our analyses lie in the large number of trials and
patients included, the geographic diversity of patient populations,
standardization of SGRQ instrument administration, and general
similarity of baseline characteristics of patients across trials. While
one might expect differences in health status perception across
different cultures, the consistency of results suggests that such
differences did not excessively distort the overall ﬁndings. It may be
questioned whether 6 months (the duration of four of the 10
HandiHaler trials) is sufﬁcient to assess the maximum effect of
tiotropium on SGRQ. However, in the trials of longer duration with
both the HandiHaler and Respimat inhalers, adjusted mean differ-
ence in SGRQ total score from baseline between treatments at 6
months and 1 year were similar.
The trials considered in these analyses spanned a considerable
period of time (1997e2010) during which substantial changes in
COPD management occurred [39,40]. Such changes may have
altered the pattern of impairment, e.g., death rates [41,42], exac-
erbation rates, and hospitalizations [43] in patients with COPD, yet
the pattern of efﬁcacy regarding SGRQ response appears to have
persisted.
A limitation of the analysis is that it is based on data from
randomized controlled clinical trials, and may not be generalizable
to clinical practice because of the exclusion and inclusion criteria
employed. However, a recent comparison of baseline demographics
in patients in 35 tiotropium HandiHaler and Respimat studies,
which included all the trials in our analysis, found patients' clinical
characteristics were quite representative of patients in “real-world”
settings [44].
5. Conclusions
Tiotropium maintenance treatment via either HandiHaler or
Respimat inhalers improved HRQoL in patients with moderate-to-
very severe COPD, expressed in the conventional manner (SGRQ
total score) and in alternative forms as different measures of SGRQ
response/deterioration. These results may serve as a benchmark for
assessments of the beneﬁcial impact of other treatments used in
COPD on health status.
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